Design and interpretation of studies of the risk of cancer and other long-term morbidity and mortality after growth hormone treatment

Growth Hormone and IGF Research

Volumn 10, Issue 6, 2000, Pages 318-323

  Swerdlow, A J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

AGE; CANCER RISK; CHILDHOOD LEUKEMIA; ETHNOLOGY; FOLLOW UP; HORMONAL THERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SEX;

EID: 0034493072     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1054/ghir.2000.0174     Document Type: Review

References (14)

1. GH, IGF-I, and the risk of cancer: An epidemiological perspective
2. Growth hormone therapy and leukaemia
3. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan
4. Brain tumor recurrence in children treated with growth hormone: The National Cooperative Growth Study experience
5. Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism
6. Does growth hormone therapy increase the frequency of tumor recurrence in children with brain tumors?
7. Risk of leukemia in children treated with human growth hormone: Review and reanalysis
8. Risk of leukemia after treatment with pituitary growth hormone
9. Health information resources in the United Kingdom
10. Human pituitary growth hormone (hGH) and Creutzfeld-Jakob disease: Results of an epidemiological survey in France, 1986
11. Mortality, neoplasia, and Creutzfeld-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom
12. Second cancers after treatment of Hodgkin's disease
13. Premature mortality due to cardiovascular disease in hypopituitarism
14. Increased cerebrovascular mortality in patients with hypopituitarism